{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:59:24Z","timestamp":1780750764759,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":31,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_8","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:01:56Z","timestamp":1753707716000},"page":"133-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45\u201355 Skipping Accompanied by Rescue of Dystrophin Expression"],"prefix":"10.1007","author":[{"given":"Joshua A.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Duddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin\u2019ichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"1","key":"8_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Krieg AM (2017) FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen saga. Nucleic Acid Ther 27(1):1\u20133","journal-title":"Nucleic Acid Ther"},{"issue":"5","key":"8_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther 25(5):1069\u20131075","journal-title":"Mol Ther"},{"issue":"10063","key":"8_CR3","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J et al (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388(10063):3017\u20133026","journal-title":"Lancet"},{"issue":"18","key":"8_CR4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377(18):1723\u20131732","journal-title":"N Engl J Med"},{"issue":"27","key":"8_CR5","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805\u20132816","journal-title":"N Engl J Med"},{"issue":"9719","key":"8_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ et al (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719):998\u20131006","journal-title":"Lancet"},{"key":"8_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.42","volume":"5","author":"C Stein","year":"2016","unstructured":"Stein C, Castanotto D, Krishnan A et al (2016) Defibrotide (Defitelio): a new addition to the stockpile of Food and Drug Administration-approved oligonucleotide drugs. Mol Ther Nucleic Acids 5:e346","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"8_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144\u2013176","journal-title":"J Pers Med"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545","journal-title":"Drug Des Devel Ther"},{"key":"8_CR10","doi-asserted-by":"crossref","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med 7(4)","DOI":"10.3390\/jpm7040013"},{"issue":"6","key":"8_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919\u2013928","journal-title":"Cell"},{"issue":"16","key":"8_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","volume":"364","author":"NM Goemans","year":"2011","unstructured":"Goemans NM, Tulinius M, van den Akker JT et al (2011) Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy. N Engl J Med 364(16):1513\u20131522","journal-title":"N Engl J Med"},{"key":"8_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.6","volume":"3","author":"QL Lu","year":"2014","unstructured":"Lu QL, Cirak S, Partridge T (2014) What can we learn from clinical trials of exon skipping for DMD? Mol Ther Nucleic Acids 3:e152","journal-title":"Mol Ther Nucleic Acids"},{"issue":"22","key":"8_CR14","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2016.16437","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J (2016) Approving a problematic muscular dystrophy drug: implications for FDA policy. JAMA 316(22):2357\u20132358","journal-title":"JAMA"},{"issue":"4","key":"8_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura A, Shiba N, Miyazaki D et al (2017) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62(4):459\u2013463","journal-title":"J Hum Genet"},{"issue":"7","key":"8_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jocn.2006.12.012","volume":"15","author":"A Nakamura","year":"2008","unstructured":"Nakamura A, Yoshida K, Fukushima K et al (2008) Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 15(7):757\u2013763","journal-title":"J Clin Neurosci"},{"issue":"1","key":"8_CR17","first-page":"9","volume":"34","author":"A Taglia","year":"2015","unstructured":"Taglia A, Petillo R, D\u2019Ambrosio P et al (2015) Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene. Acta Myol 34(1):9\u201313","journal-title":"Acta Myol"},{"issue":"1","key":"8_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines6010001","volume":"6","author":"T Aslesh","year":"2018","unstructured":"Aslesh T, Maruyama R, Yokota T (2018) Skipping multiple exons to treat DMD \u2013 promises and challenges. Biomedicines 6(1):1","journal-title":"Biomedicines"},{"issue":"5","key":"8_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/hgtb.2012.117","volume":"23","author":"K Anthony","year":"2012","unstructured":"Anthony K, Feng L, Arechavala-Gomeza V et al (2012) Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen. Hum Gene Ther Methods 23(5):336\u2013345","journal-title":"Hum Gene Ther Methods"},{"issue":"9","key":"8_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162467","volume":"11","author":"RC Verheul","year":"2016","unstructured":"Verheul RC, van Deutekom JC, Datson NA (2016) Digital droplet PCR for the absolute quantification of exon skipping induced by antisense oligonucleotides in (pre-)clinical development for Duchenne muscular dystrophy. PLoS One 11(9):e0162467","journal-title":"PLoS One"},{"issue":"22","key":"8_CR21","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1212\/WNL.0000000000001025","volume":"83","author":"K Anthony","year":"2014","unstructured":"Anthony K, Arechavala-Gomeza V, Taylor LE et al (2014) Dystrophin quantification: biological and translational research implications. Neurology 83(22):2062\u20132069","journal-title":"Neurology"},{"issue":"3","key":"8_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.pmr.2012.06.006","volume":"23","author":"NC Joyce","year":"2012","unstructured":"Joyce NC, Oskarsson B, Jin LW (2012) Muscle biopsy evaluation in neuromuscular disorders. Phys Med Rehabil Clin N Am 23(3):609\u2013631","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"8296150","DOI":"10.1155\/2016\/8296150","volume":"2016","author":"R Paasuke","year":"2016","unstructured":"Paasuke R, Eimre M, Piirsoo A et al (2016) Proliferation of human primary myoblasts is associated with altered energy metabolism in dependence on ageing in vivo and in vitro. Oxidative Med Cell Longev 2016:8296150","journal-title":"Oxidative Med Cell Longev"},{"issue":"11","key":"8_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/sj.ejhg.5201465","volume":"13","author":"T Lalic","year":"2005","unstructured":"Lalic T, Vossen RH, Coffa J et al (2005) Deletion and duplication screening in the DMD gene using MLPA. Eur J Hum Genet 13(11):1231\u20131234","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"8_CR25","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1212\/WNL.57.4.574","volume":"57","author":"F Muntoni","year":"2001","unstructured":"Muntoni F (2001) Is a muscle biopsy in Duchenne dystrophy really necessary? Neurology 57(4):574\u2013575","journal-title":"Neurology"},{"issue":"1","key":"8_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9(1):77\u201393","journal-title":"Lancet Neurol"},{"issue":"1","key":"8_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.59566\/IJBS.2008.4014","volume":"4","author":"Z Liu","year":"2008","unstructured":"Liu Z, Fan H, Li Y et al (2008) Experimental studies on the differentiation of fibroblasts into myoblasts induced by MyoD genes in vitro. Int J Biomed Sci 4(1):14\u201319","journal-title":"Int J Biomed Sci"},{"issue":"6","key":"8_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/0092-8674(87)90585-X","volume":"51","author":"RL Davis","year":"1987","unstructured":"Davis RL, Weintraub H, Lassar AB (1987) Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51(6):987\u20131000","journal-title":"Cell"},{"issue":"8","key":"8_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012239","volume":"5","author":"T Saito","year":"2010","unstructured":"Saito T, Nakamura A, Aoki Y et al (2010) Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 5(8):e12239","journal-title":"PLoS One"},{"key":"8_CR30","first-page":"S41","volume-title":"Molecular therapy","author":"Y Echigoya","year":"2014","unstructured":"Echigoya Y, Duddy W, Lee J et al (2014) Exons 45-55 skipping of human dystrophin transcripts using cocktail antisense oligonucleotides. In: Molecular therapy, vol 22. Nature Publishing Group, New York, pp S41\u2013S42"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-7374-3_10","volume":"1687","author":"T Shimo","year":"2018","unstructured":"Shimo T, Maruyama R, Yokota T (2018) Designing effective antisense oligonucleotides for exon skipping. Methods Mol Biol 1687:143\u2013155","journal-title":"Methods Mol Biol"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:08:06Z","timestamp":1780747686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":31,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_8","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}